Equivir/Equivir G
Solid Tumors
Key Facts
About Impact Biomedical
Impact Biomedical Inc. is a U.S.-based public biotech company focused on translating its proprietary platform technologies into novel therapeutics for oncology and virology. The company's strategy centers on advancing its Equivir platform for viral oncolysis and its SnapCure platform for antibody discovery through internal R&D and strategic collaborations. While still pre-revenue and in early clinical/preclinical stages, its platform-based approach aims to generate multiple high-value product candidates, though it faces significant execution and funding risks typical of micro-cap biotechs.
View full company profileAbout Impact Biomedical
Impact Biomedical Inc. is a U.S.-based public biotech company focused on translating its proprietary platform technologies into novel therapeutics for oncology and virology. The company's strategy centers on advancing its Equivir platform for viral oncolysis and its SnapCure platform for antibody discovery through internal R&D and strategic collaborations. While still pre-revenue and in early clinical/preclinical stages, its platform-based approach aims to generate multiple high-value product candidates, though it faces significant execution and funding risks typical of micro-cap biotechs.
View full company profileOther Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |